ESR1 and breast cancer: Notably, OP‐2 is the only KAT6 inhibitor to demonstrate dose‐dependent synergism with palbociclib and palazestrant (a complete ER antagonist) in T47D cells, indicating a new combination strategy for ER+ breast cancer.